Skip to main content

Table 2 SAX treatments characteristics

From: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

 

N = 148

(%)

First line

 Sutent

148

100

Sutent schedule

 Modified

27

18

 Standard

121

82

Axitinib dose

 Standard

113

76.4

 Titration

35

23.6

Therapy after axitinib

73

49

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us